stonks4u
Log inSign up free
NSRX logo

NSRX Nasus Pharma Ltd.

New York Stock Exchange Arca · Medical - Pharmaceuticals · Healthcare

$3.50
-0.13 (-3.45%)

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001…

Market Cap: $30.10Mwww.nasuspharma.com

Price

No data yet.

Signal Score (90d)

100
100
Aug 17Aug 17

Quote

Day Range
$3.48 – $3.70
52-Week Range
$1.98 – $9.99
Volume
$1.9K
Market Cap
$30.10M
50-Day Avg
$3.18
200-Day Avg
$4.63
Prev Close
$3.62
Open
$3.70

Valuation & Ratios

P/E Ratio
-48.53
EPS
$-0.17
P/B Ratio
0.00
P/S Ratio
0.00
Debt/Equity
0.00
Current Ratio
0.00
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
+0.0%
Return on Assets
+0.0%
FCF Yield
+0.0%
EV/EBITDA
0.00

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2024$0.00$-1.53M$-0.17
2023$0.00$-1.05M$-0.12
2022$0.00$-1.71M$-0.19

Social Signal Score

50
5d
51
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1

Insider trading

Open-market buys and sells by NSRX officers and directors.

Bought
$62k

3 trades

Sold
—

0 trades

  • Teleman Dan Benjaminbought
    director, officer: Chief Executive Officer·6,550 @ $3.10·$20k·Jun 17, 2026·filing
  • Teleman Dan Benjaminbought
    director, officer: Chief Executive Officer·2,900 @ $3.76·$11k·Apr 22, 2026·filing
  • Teleman Dan Benjaminbought
    director, officer: Chief Executive Officer·15,000 @ $2.04·$31k·Mar 31, 2026·filing

17 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

NSRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsglobenewswire.com·6h ago·Neutral

    …Officer Company on Track to Advance Clinical Programs to Key Second Half 2026 Milestones TEL AVIV, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced its financial results for the six months ending June 30, 2026 and provided a corporate update.

    View source ↗